MRMarta Del Valle Rubido

Marta Del Valle Rubido

*This is an algorithmically generated author record based on publicly available information.

Marta Del Valle Rubido has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Daniel Umbricht

    Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, NRD, Basel, Switzerland

    3 shared publications
  • Eric Hollander

    Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine and Montefiore Medicine, Bronx, NY, USA

    3 shared publications
  • Frederick Shic

    Center for Child Health, Behavior and Development, Seattle Children's Research Institute, Seattle, WA, USA

    3 shared publications
  • James T. McCracken

    Psychiatry and Behavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    3 shared publications
  • Jana Noeldeke

    Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, NRD, Basel, Switzerland

    3 shared publications
  • Lauren Boak

    Roche Product Development Neuroscience, Basel, Switzerland

    3 shared publications

Latest Publications

  • Open Access

    Correction to: Exploring Social Biomarkers in High‑Functioning Adults with Autism and Asperger’s Versus Healthy Controls: A Cross‑Sectional Analysis

    by Marta Del Valle Rubido, Eric Hollander, James T. McCracken, Frederick Shic, Jana Noeldeke, Lauren Boak, Omar Khwaja, Shamil Sadikhov, Paulo Fontoura, Daniel Umbricht

    The original version of this article unfortunately contained a mistake in CI values in Table 2.

  • Open Access

    Exploring Social Biomarkers in High-Functioning Adults with Autism and Asperger’s Versus Healthy Controls: A Cross-Sectional Analysis

    by Marta Del Valle Rubido, Eric Hollander, James T. McCracken, Frederick Shic, Jana Noeldeke, Lauren Boak, Omar Khwaja, Shamil Sadikhov, Paulo Fontoura, Daniel Umbricht

    Biomarkers for autism spectrum disorder (ASD) are lacking but would facilitate drug development for the core deficits of the disorder. We evaluated markers proposed for characterization of differences in social communication and interaction in adults with ASD versus healthy controls (HC) for utility as biomarkers. Data pooled from an observational study and baseline data from a placebo-controlled study were analyzed. Between-group differences were observed in eye-tracking tasks for activity monitoring, biomotion, human activity preference, composite score (p = 0.0001–0.037) and pupillometry (various tasks, p = 0.017–0.05). Impaired olfaction was more common in the ASD sample versus HC (p = 0.018). Our preliminary results suggest the potential use for stratification and response sub-analyses outcome-prediction of specific eye-tracking tasks, pupillometry and olfaction tests in ASD trials


  • Open Access

    In Search of Biomarkers for Autism Spectrum Disorder

    by Marta Del Valle Rubido, James T. McCracken, Eric Hollander, Frederick Shic, Jana Noeldeke, Lauren Boak, Omar Khwaja, Shamil Sadikhov, Paulo Fontoura, Daniel Umbricht

    Autism Spectrum Disorder (ASD) lacks validated measures of core social functions across development stages suitable for clinical trials. We assessed the concurrent validity between ASD clinical measures and putative biomarkers of core deficits, and their feasibility of implementation in human studies. Datasets from two adult ASD studies were combined (observational study [n = 19] and interventional study baseline data [n = 19]). Potential biomarkers included eye‐tracking, olfaction, and auditory and visual emotion recognition assessed via the Affective Speech Recognition test (ASR) and Reading‐the‐Mind‐in‐the‐Eyes Test (RMET). Current functioning was assessed with intelligence quotient (IQ), adaptive skill testing, and behavioral ratings. Autism severity was determined by the Autism Diagnostic Observation Scale‐2 and Social Communication Interaction Test (SCIT). Exploratory measures showed varying significant associations across ASD severity, adaptive skills, and behavior. Eye tracking endpoints showed little relationship to adaptive ability but correlated with severity and behavior. ASR scores significantly correlated with most adaptive behavior domains, as well as severity. Olfaction predicted visual and auditory emotion recognition. SCIT scores related moderately to multiple severity domains, and was the only measure not related with IQ. RMET accuracy was less related to ASD features. Eye tracking, SCIT, and ASR showed high test–retest reliability. We documented associations of proximal biomarkers of social functioning with multiple ASD dimensions. With the exception of SCIT, most correlations were modest, limiting utility as proxy measures of social communication. Feasibility and reliability were high for eye‐tracking, ASR, and SCIT. Overall, several novel experimental paradigms showed potential as social biomarkers or surrogate markers in ASD. Autism Research 2018, 11: 1567–1579. © 2018 The Authors. Autism Research published by International Society for Autism Research and Wiley Periodicals, Inc.Lay Summary: More accurate measurements of treatment effects are needed to help the development of new drug treatments for autism spectrum disorders (ASD). This study evaluates the relationship between assessments designed to measure behaviors associated with social communication and cognition in ASD with clinical and diagnostic assessments of symptom severity as well as their implementation. The assessments including eye‐tracking, auditory and visual social stimuli recognition, and olfaction identification showed potential for use in the evaluation of treatments for social difficulties in ASD.


  • Adaptive behavior in autism: Minimal clinically important differences on the Vineland‐II

    by C. H. Chatham, K. I. Taylor, T. Charman, X. Liogier D'ARdhuy, E. Eule, A. Fedele, A. Y. Hardan, E. Loth, L. Murtagh, M. del Valle Rubido, et al.

    Autism Spectrum Disorder (ASD) is associated with persistent impairments in adaptive abilities across multiple domains. These social, personal, and communicative impairments become increasingly pronounced with development, and are present regardless of IQ. The Vineland Adaptive Behavior Scales, Second Edition (Vineland‐II) is the most commonly used instrument for quantifying these impairments, but minimal clinically important differences (MCIDs) on Vineland‐II scores have not been rigorously established in ASD. We pooled data from several consortia/registries (EU‐AIMS LEAP study, ABIDE‐I, ABIDE‐II, INFOR, Simons Simplex Collection and Autism Treatment Network [ATN]) and clinical investigations and trials (Stanford, Yale, Roche) resulting in a data set of over 9,000 individuals with ASD. Two approaches were used to estimate MCIDs: distribution‐based methods and anchor‐based methods. Distribution‐based MCID [d‐MCID] estimates included the standard error of the measurement, as well as one‐fifth and one‐half of the covariate‐adjusted standard deviation (both cross‐sectionally and longitudinally). Anchor‐based MCID [a‐MCID] estimates include the slope of linear regression of clinician ratings of severity on the Vineland‐II score, the slope of linear regression of clinician ratings of longitudinal improvement category on Vineland‐II change, the Vineland‐II change score maximally differentiating clinical impressions of minimal versus no improvement, and equipercentile equating. Across strata, the Vineland‐II Adaptive Behavior Composite standardized score MCID estimates range from 2.01 to 3.2 for distribution‐based methods, and from 2.42 to 3.75 for sample‐size‐weighted anchor‐based methods. Lower Vineland‐II standardized score MCID estimates were observed for younger and more cognitively impaired populations. These MCID estimates enable users of Vineland‐II to assess both the statistical and clinical significance of any observed change. Autism Res 2018, 11: 270–283. © 2017 International Society for Autism Research, Wiley Periodicals, Inc.Lay Summary: The Vineland Adaptive Behavior Scales (2nd edition; Vineland‐II) is the most widely used scale for assessing day‐to‐day “adaptive” skills. Yet, it is unknown how much Vineland‐II scores must change for those changes to be regarded as clinically significant. We pooled data from over 9,000 individuals with ASD to show that changes of 2–3.75 points on the Vineland‐II Composite score represent the “minimal clinically‐important difference.” These estimates will help evaluate the benefits of potential new treatments for ASD.